United States Patent [19]

Lever, Jr. et al.

Patent Number:

4,871,865 Date of Patent: Oct. 3, 1989

[54] TRICYCLIC AROMATIC COMPOUNDS

[75] Inventors: O. William Lever, Jr., Skillman, N.J.; Harry J. Leighton, Chapel Hill, N.C.

Burroughs Wellcome Co., Research [73] Assignee: Triangle Park, N.C.

[21] Appl. No.: 894,306

Aug. 7, 1986 [22] Filed:

[30] Foreign Application Priority Data

Aug. 17, 1985 [GB] United Kingdom 8520662

Int. Cl.4 C07D 313/12; C07C 87/459 [52] U.S. Cl. 549/354; 562/442 [58] Field of Search 549/354

[56] References Cited

U.S. PATENT DOCUMENTS

2,905,668	9/1959	Jacob et al	260/243
3,401,192	9/1968	Kollonitsch et al	
3,420,851	1/1969	Bloom et al	549/354
3,509,175	4/1970	Tretter	260/333
4,223,013	9/1980	Hu et al	435/188
4,282,365	8/1981	Rokach et al	548/252
4,307,245	12/1981	Hu et al	562/442

FOREIGN PATENT DOCUMENTS

37254 10/1981 European Pat. Off. . 92114 10/1983 European Pat. Off. . 130555 1/1985 European Pat. Off. . 1018995 2/1966 United Kingdom . 1412095 10/1975 United Kingdom .

OTHER PUBLICATIONS

B. A. Patel et al., J. Org. Chem., vol. 42(24) (1977), pp. 3903-3907.

M. Leitold et al., Arzneim.-Forsch./Drug. Res. 34(1), No. 4, (1984), pp. 468-473.

C. A. Stone et al., J. Med. Chem., vol. 8 (1965), pp. 829-835.


Wilson et al., Textbook of Organic Medicinal and Pharmaceutical Chemistry, 3rd ed. (1956), J. B. Lippincott Co., pp. 374-376.

Stedman's Medical Dictionary, 23rd ed. (1976), p. 648. Remington's Pharmaceutical Sciences, 14th ed. (1970), Mack Publ. Co., pp. 1142-1144, 1152-1153.

Primary Examiner-Richard L. Raymond Assistant Examiner-Ba Trinh Attorney, Agent, or Firm-Donald Brown

ABSTRACT [57]

The present invention relates to compounds of formula



or a salt, ester or amide thereof; wherein R¹ is —CH-2-CH₂--, CH₂--O-- or --O--CH₂--; R² and R³ are the same or different and are each hydrogen, C₁₋₄ alkyl or taken together with the nitrogen comprise a nitrogen-containing heterocyclic ring having four to six ring members; R⁴ is a single bond or a C₁₋₇ bivalent aliphatic hydrocarbon group and may be joined to the aromatic ring system at the 2,3,8 or 9 positions; n is 0 to 3, and their use as anithistamine and antiasthma agents.

3 Claims, No Drawings



TRICYCLIC AROMATIC COMPOUNDS

The present invention relates to new chemical compounds which have potent antihistaminic activity, to 5 processes for preparing them and to their use in medicine. Belg. Patent 623259, Neth. Patent Appl. 6407758, Neth, Patent Appl. 6411861 and Belg. Patent 641498 disclose a group of 11-[(dialkylamino)alkylidene]-6,11- 10 dihydrodibenz[b,e]oxepins as psychotherapeutic agents the most outstanding of which is the compound named, (11-(3-(dimethylamino)propylidene)-6,11-dihy-

drodibenz[b,e]oxepin), and hereinafter referred to by its generic name, doxepin. Doxepin has been accepted as 15 (3) an antidepressant in human clinical chemotherapy and an antipruritic for veterinary use. We have now discovered that a group of carboxylic acid derivatives of doxepin possess surprisingly potent antihistaminic and anti- 20 asthmatic properties. In this invention, compound (Z)-11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-carboxylic acid exhibits ex-

Accordingly this ivention provides a compound of 25 the formula (I),

tremely good antihistaminic activity in vivo.

or a salt, ester or amide thereof; wherein

$$R^1$$
 is $-CH_2-CH_2-, -CH_2-O-$ or $-O CH_2-;$

 R^2 and R^3 are the same or different and are each hydrogen, C1-4 alkyl or taken together with the nitrogen comprise a nitrogen-containing heterocyclic ring hav- 40 ing four to six ring members;

R⁴ is a single bond or a C₁₋₇ bivalent aliphatic hydrocarbon group and may be joined to the aromatic ring system at the 2, 3, 8 or 9 positions. n is 0 to 3.

Of the compounds of formula (I) those of formula (II), wherein R¹ is as defined herein above, and R⁵ is a single bond or -CH-CH-, are preferred.

$$\begin{array}{c|c} R^1 & \text{(II)} \\ \hline \\ R^5CO_2H & \\ \hline \\ CH(CH_2)_2N(CH_3)_2 & \end{array}$$

The most preferred compounds of formula (II), are those of formula (IIa) and formula (IIb) wherein R5 is as defined for formula (II)

$$\bigcap_{\text{CH}(\text{CH}_2)_2\text{N}(\text{CH}_3)_2}^{\text{O}} \text{(IIA)}$$

-continued (IIB) R5CO2H CH(CH₂)₂N(CH₃)₂

2

Examples of compounds of formula (IIA) include:

- (Z)-11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-carboxylic acid,
- (2) (E)-11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-carboxylic acid,
- (E)-11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-3-carboxylic acid,
- (4) (Z)-11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-3-carboxylic acid,
- (E)-11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-8-carboxylic acid,
- (Z)-11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-8-carboxylic acid,
- (E)-11-(3-(Dimethylamino)propylidene)-6,11dihydrodibenz[b,e]oxepin-9-carboxylic acid,
- (8) (Z)-11-(3—(Dimethylamino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-9-carboxylic acid,
- (9) (E)-11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acrylic acid,
- (10) (Z)-11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acrylic acid.
- Examples of compounds of formula (11B) include; (11) (E)-5-(3-(Dimethylamino)propylidene)-10,11-dihy-
- dro-5H-dibenzo[a,d]cyclohepten-3-carboxylic acid,
- (12) (Z)-5-(3-(Dimethylamino)propylidene)-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-3-carboxylic acid.

The compounds of the present invention exist in either the cis (Z) or trans (E) isomers (in relation to the bridge oxygen in the case of formula (IIA) and the acid side chain in the case of formula (IIB)). If the compounds of formula (I) or (II) contain a double bond in the acid bearing side chain, i.e. R⁴ or R⁵, there exists a second possibility of Z and E isomeric forms. All such geometric isomers and the isomeric mixture of these compounds are included within the scope of the present invention. Salts, amides and esters of the compounds of the formula (I) and (II) are included within the scope of the invention. While esters and amides of the compounds of the formulae (I) and (II) have antihistamine activity in their own right, they may also be useful (II) 50 intermediates in the preparation of the carboxy compounds of the formulae (I) and (II). Amides derived from ammonia, primary amines or amino acids, such as glycine, are particularly suitable. Suitable esters include conventional ester groups known to be useful for pro-55 tecting carboxylic acid groups such as C₁₋₆ alkyl esters wherein the alkyl group is straight or branched chain and is optionally substituted by halogen. Alkyl esters (C₁₋₄) are particularly preferred.

Solvates of the compounds of the formulae (I) and 60 (II) are also included within the scope of the present invention. Preferred solvates include hydrates and C1-4

Salts of the compounds of formula (I) may be either acid addition salts or salts formed with the carboxylic 65 acid group. Acid addition salts are preferred but salts formed from the carboxylic acid group may be particularly useful in preparing the corresponding carboxy compound. When used in medicine, the salts of the 3

compounds of formulae (I) and (II) should be both pharmacologically and pharmaceutically acceptable, but non pharmaceutically acceptable salts may conveniently be used to prepare the free active compound or pharmaceutically acceptable salts thereof and are not 5 excluded from the scope of this invention. Such pharmacologically and pharmaceutically acceptable acid addition salts include, but are not limited to, those prepared from the following acids: hydrochloric, sulphuric, nitric, phosphoric, maleic, salicylic, toluene-p- 10 sulphonic, tartaric, citric, methanesulphonic, formic, malonic, isethionic, succinic, naphthalene-2-sulphonic and benzenesulphonic. Also, pharmaceutically acceptable salts can be prepared as ammonium salts, alkaline metal or alkaline earth salts, such as sodium, 15 potassium or calcium salts of the carboxylic acid group.

The present invention also provides analogous methods for preparing compounds of formula (I), for example:

(a) (i) A compound of formula (I) may be prepared 20 via the well known Wittig method (e.g., U.S. Pat. Nos. 3,354,155 and 3,509,175) by reaction of a compound of formula (III).

$$R^{1}$$

$$R^{4}CO_{2}H$$
(III)

The Wittig reagent, $Ph_3P = CH(CH_2)_nNR_2R_3$; i.e., formula (IV), is conveniently

$$(C_6H_5)_3P = CH(CH_2)_nNR^2R^3$$
 (IV)

prepared by reacting a compound of the formula $Ph_3PCH_2(CH_2)_nNR_2R_3Br$, with a strong base, such as sodium hydride or C_{1-6} alkyl lithium in a suitable inert solvent, such as tetrahydrofuran or dimethoxyethane at or near room temperature. It will be appreciated by those skilled in the art of organic chemistry that protection of the carboxy group may be desirable or required prior to the Wittig reaction and deprotection after the reaction.

(ii) A compound of formula (I) also may be prepared 45 via the well known Grignard conditions (e.g., Belg. 623,259) in which a Grignard reagent, i.e. (R²R³NCH₂CH₂CH₂Mg X where X is a halogen atom, reacted with a compound of formula (III), followed by dehydration with a strong acid.

(b) A compound of formula (I) wherein R⁴ is a single bond can be prepared by carboxylation of a compound of formula (V)

$$\begin{array}{c|c}
R^1 & (V) \\
\hline
CH(CH_2)_nNR^2R^3
\end{array}$$

wherein \mathbb{R}^1 , \mathbb{R}^2 , \mathbb{R}^3 and n are as defined, vide supra and X is a hydrogen or halogen atom (suitably a bromine or chloride atom attached directly to the ring system in the 2, 3, 8 or 9 positions. For example, a compound of formula (V) can be treated with a metalating agent such as butyl lithium followed by a reaction with carbon dioxide. When X is hydrogen separation of isomers may be

4

required to obtain the desired compound of formula (I). When X is a halogen atom, a compound of formula (V) can be reacted with magnesium in an appropriate solvent followed by reaction with carbon dioxide via the Grignard procedure (The Merck Index, ninth ed., page ONR-38, Merck and Co., Rahway, N.J. (1976).

(c) A compound of formula (I) wherein R^4 is other than a single bond can be synthesized by reacting a compound of formula (V) (wherein X is a halogen atom) with a compound of formula (VI),

$$CH2=CH-R6-COR7 (VI)$$

wherein R⁶ is a C₁₋₅ bivalent aliphatic hydrocarbon and R⁷ is a removable carboxylic acid protecting group such as one derived from a reaction of the carboxylic acid group which has been activated (e.g. converted to an acyl chloride) with an alcohol or amine. In some cases this reaction may need to be facilitated by a palladium catalyst (J. Org. Chem. 42, 3903–3907(1977)). A variation of this method involves a reaction of a compound of formula (VII) with a compound of formula IV in a similar manner, vide supra, followed by catalytic reduction of the double bond in the carboxylic bearing side chain that followed by the Wittig reaction described in Section (a) (i) or (ii), vide supra. The carboxylic acid groups may then be regenerated by deprotection if required.

(d) When the preparation of a compound of the formula (I) wherein R⁴ is CH—CH is required, a compound of the formula (VII)

$$\mathbb{R}^{1}$$
 \mathbb{R}^{1} \mathbb{R}^{1}

wherein R¹ is as defined, vide supra and X is halogen can be reacted with acrylic acid or an acrylic acid ester, with use of a catalyst if needed, by a method analogous to that described in (b), vide supra, followed by a Wittig reaction as described in part (a) (i) or (ii), vide supra. The carboxylic acid can be regenerated by deprotection if desired.

A compound of formula (VII) may be prepared by reacting a compound of formula (VIII).

$$\mathbb{R}^1$$
 \mathbb{R}^1 \mathbb{R}^1 \mathbb{R}^1

wherein R¹ and X are as defined, vide supra with a dehydrating agent such as (CF₃CO)₂O/BF₃.OEt₂.

(e) It is possible to convert one compound of the formula (III) to another compound of the formula (III) by methods well known to those skilled in the art, for example the reduction of one or more double bonds or de-esterification of an ester group or hydrolysis of an amide, followed by a Wittig reaction with Ph₃P=CH₂(CH₂)_nNR₂R₃ as described, vide supra.

(f) A compound of formula (VIII) can be converted to a Grignard reagent or an organolithium reagent by methods well know to those skilled in the art (after protecting the CO₂H group) then reacted with dimethyl

formamide to obtain the corresponding aldehyde. Such an aldehyde can be converted to an acid by oxidation or reaction with a trialkyl phosphonium acetate or an equivalent. By methods well known in the art of organic chemistry, after deprotecting such an acid can be 5 dehydrated as described in (d), vide supra to give a compound of formula (III).

(g) A compound of the formula (V) where X is halogen can be reacted with a metal (I) cyanide, such as cuprous cyanide to give a corresponding carbonitrile 10 be administered alone as the raw chemical, it is preferaderivative, which can then be converted to compounds of formula (I), eg the carboxylic acid via hydrolysis.

Those intermediates that are novel form an important further aspect of the present invention.

(h) Interconversion of compounds of the formula (I) 15 is possible, e.g. by hydrolysis of esters, amides and by isomerization about the multiple bonds when such bonds are present or by selective reduction of multiple bonds when such bonds are present.

The compounds of this invention having antiallergic 20 activity may be used for the same indications as clinically used antiasthmatic compounds, namely to help to control bronchoconstriction or brochospasm characteristic of allergic asthma and exercise induced asthma and the symptoms of bronchoconstriction and broncho- 25 thereof. spasm resulting from acute or chronic bronchitis. The compounds are believed to inhibit the release of autacoids (i.e. histamine, serotonin and the like) from mast cells and to inhibit directly the antigen-induced production of histamine. Thus, they may be classified as mast 30 cell stabilizers with antihistaminic action.

The compounds of this invention having antihistamine activity may be used for the same indications as clinically used antihistamines, namely to relieve detrimental symptoms (caused by histamine release) of nasal 35 stuffiness due to colds and vasomotor rhinitis and for the symptomatic control of allergic conditions including nasal allergy, perennial rhinitis, urticaria, angioneurotic oedema, allergic conjunctivitis, food allergy, drug and serum reactions, insect bites and stings and desensi- 40 tions. tizing reactions. The compound may also be used in conditions response to its antipruritic activity including allergic dermatoses, neurodermatitis, anogenital pruritus, and pruritus of non-specific origin such as eczema, and of specific cause such as chickenpox, photosensitiv- 45 ity and sunburn. The present invention therefore provides a method for the symptomatic treatment of allergic conditions by the administration of an effective amount of a compound of formula (I). The present invention also provides a method for the antagonism of 50 endogenously released histamine by the administration of an effective amount of a compound of formula (I). The compounds of formula (I) are substantially free from sedative effects.

The amount of active compound, ie, a compound of 55 formula (I) required for use in the above conditions will vary with the compound chosen, the route of administration and the condition and mammal undergoing treatment, and is ultimately at the discretion of the phya mammal is in the range of from 0.003 to 1.0 mg per kilogram body weight per day; preferably from 0.04 to 0.24 mg/kg. For example a typical dose for a human recipient of compound (1), (Z)-11—(3—(dimethylamino)propylidene)—6,11—dihydrodibenz[b,e]oxepin-2-carboxylic acid, as the hydrogen chloride salt (see Example 7 and Table 1, vide infra) is between 0.03 and 0.1 mg/kg body weight per day.

The desired daily dose is preferably presented as from one to six sub-doses administered at appropriate intervals throughout the day as needed. Where three subdoses of compounds of formula (I) are employed, each will preferably lie in the range of from 0.014 to 0.08 mg/kg body weight; for example, a typical sub-dose of such a compound for a human recipient is between 1 and 20 mg, for example 4 or 8 mg.

While it is possible for a compound of formula (I) to ble to present the compound of formula (I) as a pharmaceutical formulation. Thus, the present invention also provides pharmaceutical formulations, both for veterinary and for human medical use, which comprise a compound of formula (I) together with one or more pharmaceutically acceptable carriers therefor and optionally any other therapeutic ingredients. For example, the active compound may be formulated with a sympathomimetic agent such as the decongestant pseudoephedrine, an antitussive such as codeine, an analgesic, an antiinflammatory, an antipyretic, or an expectorant. The carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient

The formulations include those suitable for oral, rectal, topical, nasal, ophthalmic or parenteral (including subcutaneous, intramuscular and intravenous) administration.

The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active compound into association with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier or a finely divided solid carrier or both and then, if necessary, shaping the product into desired formula-

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, each containing a predetermined amount of the active compound (defined herein as a compound of formula (I)); as a powder or granules; or a suspension in an aqueous liquid or nonaqueous liquid such as a syrup, and elixir, an emulsion or a draught. A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine, with the active compound being in a free-flowing form such as a powder or granules which is optionally mixed with binder, disintegrant, lubricant, inert diluent, surface active agent or dispersing agent. Molded tablets comprised of a mixture of the powdered active compound with any suitable carrier may be made by molding in a suitable

A syrup may be made by adding the active comsician. A suitable oral dose of the active compound for 60 pound to a concentrated, aqueous solution of a sugar for example sucrose to which may also be added any accessory ingredient(s). Such accessory ingredient(s) may include flavourings, an agent to retard crystallization of the sugar or an agent to increase the solubility of any other ingredient, such as a polyhydric alcohol, for example glycerol or sorbitol, and suitable preservatives.

Formulations for rectal administration may be presented as a suppository with a usual carrier such as cocoa 7

butter, or hydrogenated fats or hydrogenated fatty carboxylic acids.

Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active compound which is preferably isotonic with 5 the blood of the recipient.

Nasal spray formulations comprise purified aqueous solutions of the active compound with preservative agents and isotonic agents. Such formulations are adjusted to a pH and isotonic state compatible with the 10 nasal mucous membranes.

Ophthalmic formulations are prepared by a similar method to the nasal spray except that the pH and isotonic factors are adjusted to match that of the eye.

Topical formulations comprise the active compound dissolved or suspended in one or more media such as mineral oil, petroleum, polyhydroxy alcohols or other bases used for topical pharmaceutical formulations. The addition of other accessory ingredients, vide infra, may be desirable.

In addition to the aforementioned ingredients, the formulations of this invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavouring agents, binders, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.

The present invention also provides the first use of the compounds of formula (I) in medicine.

The following Examples are provided by the way of illustration of the present invention and should in no way be construed as a limitation thereof. All temperatures indicated are in degrees Celsius.

EXAMPLE 1

(E)/(Z)-11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-carboxylic acid

(a) 2-Bromo-6,11-dihydrodibenz[b,e]oxepin-11-one

2-Bromo-6,11-dihydrodibenz[b,e]oxepin-11-one was prepared as described in U.S. Pat. No. 4,282,365, m.p. $132^{\circ}-134^{\circ}$ C. (Lit. m.p. $136^{\circ}-139^{\circ}$ C.). pmr (DMSO/d₆) δ : 8.13 (d, J=2.6 Hz, 1H, H₁), 7.48-7.83 (m, 5H, aromatic), 7.07 (d, J=8.8 Hz, 1H, H₄), 5.31 (s, 2H, CH₂O). Analysis: Calcd. for C₁₄H₉BrO₂: C, 58.16; H, 3.14;

Br, 27.64. Found: C, 58.20; H, 3.18; Br, 27.73.

(E)/(Z)-3-(2-Bromo-6,11-dinydrodibenz[b,e]oxepin-11-ylidene)-N,N-dimethylpropylamine

Anhydrous 3-(dimethylamino)propyltriphenylphosphonium bromide hydrobromide (39.4 g., 0.08 mole) 50 was suspended in 450 mL of dry tetrahydrofuran and 100 mL of a solution of n-butyl lithium in hexane (1.6M) was added dropwise at 0° C. under a nitrogen atmosphere during a 30 minute period. After an additional 10 2-bromo-6,11-dihydrodibenz[b,eloxepin-55] 11-one (16.8 g., 0.06 mole) in 150 mL dry tetrahydrofuran was added slowly to the deep red solution and the reaction mixture was then refluxed for 18 hours. The reaction mixture was poured onto ice-water, and the mixture was extracted with diethyl ether. The ether 60 layer was concentrated under reduced pressure and the residue was suspended in water and then acidified with 6N hydrochloric acid. The acidic aqueous layer was washed with hexanes and then was concentrated to give a gummy residue. The residue was crystallized from 65 ethyl acetate/methanol to provide 5.3 g. of pure Z-isomer as its hydrochloride salt, m.p. 201°-204° C. The mother liquor was chromatographed on a silica gel

8

column (Waters Associates-Prep. 500) with ethyl acetate/methanol (8:2) to give an additional 2.55 g. of pure Z-isomer as the hydrochloride salt and 2.79 g. of E-isomer as its hydrochloride salt, m.p. 230°-233° C. pmr (Z-isomer) (DMSO/d₆) δ: 7.25-7.44 (m, 6H, aromatic), 6.81 (degenerate d, J=9.1 Hz, 1H, H₄), 5.72 (t, J=7.1 Hz, 1H, CH=), 5.22 (s, 2H, CH₂O), 3.18 (m, 2H, NCH₂), 2.70 (m, 2H, CH₂), 2.66 (s, 6H, NMe₂). pmr (E-isomer) (DMSO/d₆) δ: 7.23-7.50 (m, 6H, aromatic), 6.70 (d, J=8.6 Hz, 1H, H₄), 6.10 (t, J=7.2 Hz, 1H, CH=) 5.15 (br s, 2H, CH₂O), 3.07 (m, 2H, NCH₂), 2.65 (s, 6H, NMe₂), 2.50 (m overlap with DMSO, 2H, CH₂).

(c)

(Z)-11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-carboxylic acid (Compound 1)

A solution of n-butyl lithium in hexane (1.6M, 3.5 20 mL) was added dropwise to a solution of 1.8 g. pure (Z)-3-(2-bromo-6,11-dihydrodibenz[b,e]oxepin-11ylidene)-N,N-dimethylpropylamine in 100 mL of dry tetrahydrofuran at -70° C. under a nitrogen atmosphere. After the yellowish-orange solution was stirred at -70° C. for 10 minutes, gaseous carbon dioxide was bubbled through the reaction medium to give a pale yellow solution. The solution was allowed to warm gradually to room temperature and was then concentrated under reduced pressure. The foamy residue was dissolved in water, and the mixture was neutralized with 1N hydrochloric acid and then extracted with chloroform. Concentration of the chloroform and recyrstallization of the residue from water gave 0.5 g. pure Z-2-carboxylic acid, m.p. 121°-123° C. pmr (CDCl₃) δ : 7.87 (d, J\leq 1 Hz, 1H, H₁), 7.81 (dd, J=7.8, 2.2 Hz, 1H, H₃), 7.25-7.28 (m, 4H, aromatic), 6.82 (degenerate d, J=8.8 Hz, 1H, H₄), 6.45 (br s, 1H, CO₂H), 5.50 (m, 1H, CH=), 5.20 (br s, 2H, CH₂O), 2.92 (m, 4H, NCH₂CH₂), 2.66 (s, 6H, NMe₂).

Analysis: Calcd. for C₂₀H₂₁NO₃,0.55 H₂O: C, 72.07; H, 6.68; N, 4.20. Found: C, 72.07; H, 6.69; N, 4.18.

(d)

(E)-11-(3-(Dimethylamino)propylidine)-6,11-dihy-drodibenz[b,e]oxepin-2-carboxylic acid (Compound 2)

Pure (E)-3-(2-bromo-6,11-dihydrodibenz[b,e]oxepin-11-ylidene)-N,N-dimethylpropylamine (1.55 g., .43 mmole), was treated under nitrogen in cold (-70° C.) tetrahydrofuran (100 mL) with 4.4 mmole of n-butyl lithium in hexane followed by gaseous carbon dioxide as described for the Z-isomer (Step C). Isolation of the (E)-2-carboxylic acid was achieved by through chromatography of the crude product on a reverse phase C18 semipreparative column eluted with 20% methanol in water (containing 0.1% triethylamine). Recrystallization of the solid product from water afforded 0.012 g of pure E-2-carboxylic acid, m.p. >200° C. (decomp.). pmr (CDCl₃) δ : 7.85 (d, J=2.0 Hz, 1H, H₁), 7.06-7.78 (m, 5H, aromatic), 6.47 (d, J=8.5 Hz, 1H, H₄), 6.28 (t, J=4.2 Hz, 1H, CH=), 5.85 (m, 1H, ArCH), 4.70 (m, 1H, ArCH), 2.43 (m, 4H, NCH₂CH₂), 2.28 (s, 6H, NMe_2).

Analysis: Calcd. for C₂₀H₂₁NO₃.0.50 H₂O: C, 72.27; H, 6.67; N, 4.21. Found: C, 72.15; H, 6.46; N, 4.22.



45

DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

